Role / Responsibilities
We are seeking an experienced Computational Biologist/Bioinformatician to contribute to the Translational Genomics team at Jounce. We are looking for someone with superior technical skills who can help us use data-driven approaches to advance our programs and inform biomarker strategy. This person will lead the biomarker strategy efforts on an early stage clinical development program as well as contribute to preclinical discovery efforts. Responsibilities include implementation and maintenance of next generation sequencing (NGS) pipelines and working with teams to design experiments to interrogate immune oncology pathways. The person in this position will work closely with both bioinformatics analysts and wet lab scientists to increase team capabilities and efficiency. The ideal candidate will also act as a partner with the Research Informatics team to help build new tools and build out cloud-based bioinformatics high performance computing capabilities. Experience with clinical biomarkers is a plus. Responsibilities:
- Lead program-specific translational genomics strategy and participate in research team meetings, proactively suggest new ways to impact programs from discovery through the clinic;
- Develop novel algorithms and implement, validate, and maintain shared pipelines for processing of NGS data (targeted/whole exome, RNA, single cell, TCR, and/or BCR sequencing) and downstream analyses (e.g. TMB, HLA typing, MSI status determination, differential transcript expression);
- Evaluate and implement pipeline algorithms based on statistical quality and performance metrics on real and simulated data sets in order to keep our portfolio of tools cutting edge;
- Manage existing high-dimensional data resources and ingest new public and internal data sets for use by team members; and
- Use best practices for reproducible research and data stewardship.
StatementDiversity and Inclusion Statement
- A Ph.D. in Computational Biology, Bioinformatics, Computer Science, or a related field with 3+ years or a M.S. with 13+ years of relevant experience;
- Demonstrated problem-solving and data analytical skills;
- Highly organized and motivated individual, able to work well in a group setting as well as independently in a fast-paced environment;
- Excellent communication skills and the ability to prioritize and deliver research in a fast-paced, milestone-driven environment;
- Experience with public cancer biology databases and an understanding of how to utilize big data to drive discovery and development efforts;
- Deep understanding of next generation sequencing (NGS) methods and how upstream sample preparation and processing may affect sequencing results and their interpretation;
- Strong hands-on programming skills (R/Bioconductor, Python, SQL, Bash scripting or similar);
- Proficiency in LINUX system administration, shell scripting, software compilation, and version control systems;
- Familiarity with Amazon Web Services (AWS) or similar cloud-computing services; and
- Experience with machine learning, statistical modeling, and/or pathway/network analysis is beneficial.
Jounce strives to create a workplace that reflects the diversity of cancer patients, and where all feel included and valued because of their differences. Actively including people who add to our culture and enhance our values leads to better decisions and outcomes for those we serve patients, all patients. Beyond our walls, our focus is on addressing inequities in opportunities for STEM education, careers opportunities in Biotech, and access to cancer care. Equal Opportunity Employer
Jounce Therapeutics is an equal opportunity employer and does not discriminate in its employment decisions on the basis of race, color, national origin, age, physical or mental disability, marital status, religion, creed, sex, or political beliefs. We offer a competitive salary and benefits package. All applicants should be legally entitled to work for any employer in the U.S. Company Summary
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounces highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounces internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounces most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounces broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.